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Abstract
Despite significant recent breakthroughs, with rapid discoveries provided 
by the twentieth century, hepatic encephalopathy remains an ancestral enigma 
that accompanies the history of mankind. Much of this is due to the reductionist 
view that a single process would have primacy over others, with the emphasis on 
hyperammonemic theory being its greatest example. Since other factors, such as 
the intestinal microbiota composition, the synergism with neuroinflammation, 
and the role of glutamatergic and GABAergic tonus balance have been discovered, 
it has become clear that the traditional and linear view of scientific research allows 
the understanding of the initial state of multiple dysfunctional systems, but is 
unable to predict the overall behavior of the disease. As consequence, there is a lack 
of innovative interventions for controlled clinical trials, making its therapeutic 
management very limited. The objective of this chapter is to provide a general 
theoretical overview of the most relevant hypotheses and findings in the neurobiol-
ogy of hepatic encephalopathy, and how its toxic, metabolic and immunological 
alterations affect the cellular metabolism and neurotransmission dynamics, causing 
its characteristic cognitive and motor manifestations.
Keywords: cirrhosis, hepatic encephalopathy, cognition,  
minimal hepatic encephalopathy, motor, neurotransmission
1. Introduction
Since ancient Babylonian times (1894–1595 B.C.), people have been aware of the 
influence of liver dysfunction on cognition [1]. In the Ancient Orient, the liver was 
considered the center of life and mental activity. Hippocrates (460–370 B.C.) and 
Celsus (25 B.C.–50 A.D.) were pioneers in the description of behavioral disorders 
associated with the hepatic failure. In the Corpus Hippocraticum, there is the report 
of a patient with jaundice who “barked like a dog, could not be contained, and said 
nothing understandable” [2]. Galenus (129–199 A.D.), physician of the Roman 
centurions, considered the liver responsible, alongside the heart and the brain, for 
the triple control of the natural, animal and vital spirits. In his theory, he imagined 
that these spirits were derived from food processing and routed through the blood-
stream to the cerebral ventricles [3]. In the Modern Age, especially in the eighteenth 
century, several records of neuropsychiatric disorders in cirrhotic patients have been 
described. It is from that time that Giovanni Battista Morgagni (1682–1771 A.D.) 
detailed the progressive nature of the disease in the famous De Sedibus et Causis 
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Morborum Per Anatomen Indagatis (1761). In the Contemporary Age, Friedrich 
Theodor von Frerichs (1819–1885 A.D.) carried out an extensive documentation of 
the cognitive and motor changes found in cirrhosis [2]. In the twentieth century, 
especially since the 1930s, several publications have enumerated the typical altera-
tions in the disorder known as hepatic encephalopathy, with particular emphasis 
on the hypothesis that its pathophysiology would be caused, in some way, by the 
reduction of ammonia clearance produced in the gut [4].
The mechanisms of hepatic encephalopathy, however, remain far from being 
fully elucidated. No significant breakthrough occurred simultaneously in clinical and 
basic research in the second half of the twentieth century. Indeed, up to the present 
moment, in the twenty-first century, it seems unlikely that any new paradigm will 
emerge in a short term. In consequence, there is a lack of innovative interventions for 
controlled clinical trials, making its therapeutic management very limited [5].
The American and European Associations for the Study of the Liver (AASLD 
and EASL) define hepatic encephalopathy as “a brain dysfunction caused by liver 
insufficiency and/or portosystemic shunt” and add that “it manifests as a wide 
spectrum of neurological or psychiatric abnormalities ranging from subclinical 
alterations to coma” [6]. Such a definition encompasses the need for detection, 
quantification, and differentiation of other conditions that affect cognition, regard-
less of insufficiency and shunt. Unfortunately, little attention has been paid to the 
importance of the differential diagnosis of secondary causes of cognitive deficits 
in patients with cirrhosis [5]. In the practice of a reference unit in Brazil, 84% of 
the studied population had a concomitant condition that justified or aggravated 
the cognitive dysfunction, such as interferon use, major psychiatric illness (mainly 
depression), diabetes mellitus, neoplastic disease, use of psychotropic drugs, hypo-
thyroidism, visual impairment, use of illicit drugs, chronic obstructive pulmonary 
disease, heart failure, HIV seropositivity, and vitamin B12 deficiency [7].
Approximately 30–50% of patients with chronic liver diseases, such as cirrhosis, 
have minimal hepatic encephalopathy, with decreased information processing 
speed, attention deficits, and motor incoordination. There is evidence that even 
minimal cognitive deficits can have a major impact on quality of life, with decreased 
learning and driving ability, as well as increased caregiver overload [5]. The 2014 
Practice Guideline on Hepatic Encephalopathy describes minimal hepatic encepha-
lopathy as a condition in which there are “psychometric or neuropsychological 
alterations of tests exploring psychomotor speed/executive functions or neurophys-
iological alterations without clinical evidence of mental change” [6]. This definition 
has a primary requisite that patients do not present any clinically evident manifesta-
tions of cerebral dysfunction in the clinical evaluation. The Guideline Development 
Group suggests that the operational criterion for the diagnosis of this condition 
should be “abnormal results of psychometric and neuropsychological tests without 
any clinical manifestations”, although it is clear that there are no universal diagnos-
tic criteria and that, therefore, local testing standards are necessary [8].
To overcome all difficulties related to the understanding of hepatic encephalopathy, 
it is essential to establish a common language among the several research areas related 
to the disease. The aim of this chapter is to provide a general theoretical overview of 
the most relevant hypotheses and findings in the neurobiology of hepatic encephalopa-
thy, in order to contribute to the construction of an integrated approach to the subject.
2. The role of intestinal microbiota and enterocytes
Since the 1930s, ammonia has been known to play an important role in the 
pathophysiology of hepatic encephalopathy [4]. However, hyperammonemia can be 
3The Neurobiology of Hepatic Encephalopathy
DOI: http://dx.doi.org/10.5772/intechopen.86320
found in patients without hepatic encephalopathy, and normal levels of ammonia 
can be seen in patients with advanced hepatic encephalopathy [9]. Serum ammonia 
dosage is also not a good parameter for evaluating the severity of the disease [10]. 
In addition, studies have demonstrated that hyperammonemia is not a sufficient 
condition to produce cognitive deficits in minimal hepatic encephalopathy [11].
Ammonia is produced in the body from the metabolism of intermediate amino 
acids, and its concentration is increased by the action of intestinal bacteria. In 
adults, approximately 1000 mmol (17 g) of ammonia is produced per day [12]. In 
cirrhotics, its serum concentration increases two to three times, an increase that is 
also exacerbated by the induction of glutaminase expression by enterocytes, which 
hydrolyzes the amino acid glutamine into glutamate and ammonia to obtain energy 
[9]. At least one haplotype of the glutaminase gene appears to be related to a higher 
propensity to develop clinically symptomatic encephalopathy, demonstrating that 
the constitutive activity of this enzyme undergoes genetic variations [13].
The small and large intestines are colonized by a massive variety of microorgan-
isms, collectively known as microbiota. About two-thirds of the gut microbiota 
is unique to each individual, being composed of more than a thousand species of 
bacteria, although less than 170 commensals predominate, such as Bacteroides and 
Firmicutes [14]. Some studies have shown that the composition of the intestinal 
microbiota affects the severity of hepatic encephalopathy by modulating its toxico-
logical profile [15].
Recently, the concept of intestinal dysbiosis has been highlighted as a risk factor 
for the development of hepatic encephalopathy [5]. It refers to changes in bacterial 
composition, with a decrease in the rate of potentially beneficial autochthons and an 
increase in the rate of pathogens such as Staphylococcaceae, Enterobacteriaceae, and 
Enterococcaceae [9]. Such alterations potentiate ammonia synthesis and a proinflam-
matory systemic environment, contributing to neuroinflammation [14]. One of the 
major obstacles in assessing the impact of these changes, however, is that the compo-
sition of the microbiota varies according to geographic differences, making it practi-
cally impossible to compare individuals from different cultures and environments [9].
The use of non-absorbable disaccharides (e.g., lactulose and lactitol) remains the 
mainstay for the treatment and secondary prevention of hepatic encephalopathy. 
Although widely known for their laxative properties and their capacity to inhibit glu-
taminase activity, they have the ability to modify positively the intestinal microbiota, 
inducing the growth of commensal microorganisms. The 2014 Guideline on hepatic 
encephalopathy does not recommend its use for the treatment of minimal hepatic 
encephalopathy, but states that exceptions can be made on a case-by-case basis if 
there is impairment in driving ability, work performance, or quality of life [16].
3. The role of hepatocytes and endothelial cells
Ammonia reaches the liver through the portal circulation and is purified by peri-
portal hepatocytes, which incorporate it into urea synthesis, or by perivenular hepa-
tocytes, which catalyze the condensation of glutamate and ammonia into glutamine 
by the action of glutamine synthetase [9]. The ammonia concentration in the portal 
vein ranges from 300 to 600 μmol, dropping to 20–60 μmol in the hepatic veins 
[12]. The liver, thus, plays a central role in the regulation of its levels and, in healthy 
individuals, removes it almost completely: small amounts of escaping ammonia are 
metabolized in the skeletal muscle (which also expresses glutamine synthetase), and 
in the kidneys (where more than 70% of it is reabsorbed). In case of hepatic failure 
and portosystemic shunt, ammonia escapes this detoxification process, increasing 
its serum concentration [9]. This leads the skeletal muscle to play an important role 
Liver Disease and Surgery
4
in its clearance, but this metabolic pathway is not sufficient to eliminate it from the 
body and there is a loss of muscle mass in about 40–76% of those with cirrhosis [17]. 
Moreover, it is common for such patients to have concomitant zinc deficiency, an 
important cofactor for glutamine synthetase, which may aggravate its elimination [9].
In cirrhosis, hepatic gluconeogenesis is impaired. The amino acid precursors of 
glucose synthesis, such as alanine, threonine, glycine, and aspartate, are increased, 
whereas peripheral anaerobic glycolysis increases lactate and pyruvate levels [18]. Of 
particular importance, studies demonstrate that glycine may be an ammoniagenic 
amino acid, causing increased ammonia synthesis in the gut and brain through 
induction of a reaction mediated by glycine oxidase [19]. This has been explored as 
a potential therapeutic target, since the reaction is bi-directional and the removal of 
glycine can lead to the use of ammonia to replenish its stocks, lowering its levels [20].
On the other hand, the low systemic availability of glucose causes hepatocytes 
to produce more ketone bodies from fatty acids, for the energetic metabolism of 
nervous and muscular tissues. However, it is hypothesized that in situations like this, 
hepatocytes prioritize the production of energy for its own subsistence rather than 
synthesizing products destined for exportation to other tissues [18]. Thus, ketogen-
esis would also be impaired, which is corroborated by significantly decreased beta-
hydroxybutyrate and acetoacetate levels, resulting in a precarious energy metabolism 
in the central nervous system in the advanced stages of the disease [18, 21].
Given its location and abundant vascular supply, with immense exposure to 
antigens absorbed by the intestine, the liver regulates important immune functions 
[9]. In cirrhosis, intestinal bacterial overgrowth associated with hepatocellular fail-
ure triggers a systemic immune reaction, bypassing endotoxins such as membrane 
lipopolysaccharides, flagellins, and peptidoglycans for arterial circulation [15, 22]. 
Circulating cytokines, such as tumor necrosis factor alpha (TNFα), interleukin 1b 
(IL-1b) and interleukin 6, induce the synthesis of nitric oxide and prostanoids in 
endothelial cells, triggering a state of inflammatory hyperemia that facilitates the 
uptake of ammonia by the central nervous system [9]. In addition, the proinflam-
matory cytokines generated by the vascular endothelium activate the cells of the 
immune system in the brain parenchyma and the microglia, contributing indirectly 
to neuroinflammation [11].
4. The role of astrocytes
Astrocytes are part of the blood-brain barrier and protect neurons from the 
toxic effects of ammonia [12]. Its perivascular extensions are rich in aquaporin 4, 
a protein constituent of water channels. Astrocytes are among the cells with the 
highest glycolytic activity of the central nervous system and are estimated to be 
responsible for 30% of its metabolism. They are believed to be particularly suscep-
tible to the development of edema because they are part of the glymphatic system 
[23], a paravascular system discovered in 2012, which receives continuous influx of 
periarterial cerebrospinal fluid and has a leakage network through the perivascular 
spaces into the cerebral veins [24].
Liver failure can result in an uncontrollable rise in ammonia levels, which pene-
trate virtually all organs. Although the central nervous system is partially protected 
by the blood-brain barrier, which remains relatively intact until advanced stages of 
the disease, excessive amounts of ammonia can overtake it [12, 25]. Therefore, con-
centrations that normally range from 0.2 to 0.3 μmol in normal subjects can reach 
the mark of 3 to 5 mmol in patients with hepatic encephalopathy [4]. However, 
along with perivenular hepatocytes and skeletal muscle, astrocytes express gluta-
mine synthetase and have the ability to convert ammonia into glutamine [4, 9].
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The accumulation of glutamine in astrocytes, although not directly toxic, drasti-
cally affects its functioning [26]. Firstly, glutamine has an osmotic action, inducing 
predominantly cytotoxic and slightly vasogenic edema [25]. Generally, any  
form of edema increases the distance for diffusion of oxygen and metabolites in 
the brain parenchyma, exposing microareas of borderline irrigation to hypoxia 
[23]. This phenomenon is more pronounced in acute hepatic failure, in which the 
counterregulatory mechanisms do not have time to act, but can also be detected in 
the magnetic resonance imaging (MRI) of patients with chronic liver failure [9, 26]. 
Secondly, exceeding glutamine is transported to the mitochondria, where, by 
glutaminase action, it is hydrolyzed back into glutamate and ammonia. The passage 
of the latter to the interior of the mitochondria causes oxidative stress and modifies 
the internal mitochondrial membrane diffusivity, through the opening of perme-
ability transition pore, causing water accumulation in the mitochondrial matrix, 
low capacity of oxidative phosphorylation, and low adenosine triphosphate (ATP) 
production [11, 12]. This results in a vicious cycle of formation of reactive oxygen 
and nitrogen species (free radicals) with mitochondrial damage [9].
Studies with cultures of astrocytes and neurons show that only the former increase 
the production of free radicals when exposed to glutamine [12] and that’s why astro-
cytes can be considered the basic morphofunctional unit of hepatic encephalopathy: 
the histopathological milestone of the disease is the swelling of astrocytes, both in the 
cytoplasm and in the nucleus, with chromatin marginalization, prominent nucleoli 
and glycogen accumulation, accompanied by little neuronal alteration [4, 27].
The effects of chronic hyperammonemia and astrocytic edema can be verified 
in specific sequences of brain MRI. In the spectroscopy of the basal ganglia, the 
Glx/ creatine ratio is increased and myo-inositol/ creatine and choline/ creatine 
ratios are decreased [14, 22]. Creatine is a constitutive marker of neurons and 
astrocytes. The increase of Glx demonstrates the accumulation of glutamine and 
glutamate [22]. This increase, however, seems to present large interindividual vari-
ations, and within a same animal model, there are forms in which there is a gradual 
increase, a strong increase followed by a plateau or only by a late rise [21]. Choline 
is a marker for the turnover of membrane phospholipids, and its decrease reflects 
reduction of basal metabolism of neurons and glial cells [22]. Furthermore, due to 
the osmotic imbalance generated by the accumulation of glutamine and glutamate, 
astrocytes export choline and myo-inositol, its main osmolyte, to the extracellular 
space, which leads to a reduction in the levels of the later, in an attempt to counter-
balance the intracellular edema. This mechanism is known as regulatory volume 
decrease [11, 21, 23]. The diffusion-weighted imaging, in turn, shows interstitial 
edema resulting from the exportation of osmolytes from the astrocytes into the 
extracellular space, both in the white and gray matters. Because of that, multiple 
sites in the brain have an increase in mean diffusivity, including the frontal, tem-
poral, inferior parietal, and insular lobes, as well as the corpus callosum, putamen, 
thalamus, and pons [22, 27]. The diffusion of water molecules, however, is not free; 
it reflects interactions with macromolecules, fibers, and membranes. It is impor-
tant to emphasize that the diffusion-weighted sequences only show changes in the 
intra- and extracellular volume, and do not allow a definitive conclusion about the 
total amount of water present in the brain parenchyma [23].
5. The role of microglial cells
The activity of astrocytes and neurons can be modulated by microglia. The microg-
lial cells are innate of the immune system, have phagocytic function and perform 
active surveillance of the brain parenchyma. In the absence of inflammatory stimuli, 
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they remain quiescent and have an aspect endowed with ramifications (resting pheno-
type). When an inflammatory stimulus occurs, they become reactive and acquire an 
ameboid aspect (active phenotype), migrating to the injured site, where they prolifer-
ate and produce neurotoxic and neurotrophic factors that control tissue damage and 
regeneration. In hepatic encephalopathy, molecules such as ammonia, glutamate, and 
some locally produced neuroactive steroids (neurosteroids) may trigger the transition 
from the resting phenotype to the active phenotype [11].
Neuroinflammation modulates glutamatergic activity. Studies have shown that 
microglial activation in the cerebellum of rats exposed to chronic hyperammonemia 
promotes an increase in the production of proinflammatory cytokines, such as 
TNFα and IL-1b, in addition to an increase in the expression of TNFα receptors. 
Of particular importance, TNFα receptors are also expressed on the surface of 
astrocytes and their stimulation induces increased glutaminase, contributing to the 
increase of glutamate synthesis [28]. There is also evidence that excess glutamate 
causes microglial activation, resulting in an intercellular vicious cycle [11].
Another important neurotransmission system affected by neuroinflammation 
includes a class of peripheral gamma-aminobutyric acid (GABA) receptor, known 
as translocator protein (TSPO), which is expressed in the outer mitochondrial 
membrane of neurons. Although poorly present under normal conditions, microg-
lial activation strongly increases its concentration, which can be seen in cirrhotic 
patients through studies with positron emission tomography and carbon 11-labeled 
radiotracer that specifically bind to it [11]. It is known that TSPO mediates the 
synthesis of neurosteroids from cholesterol, and its increased expression provides an 
important link between neuroinflammation and increased GABAergic activity [12].
Like hyperammonemia, neuroinflammation is not sufficient to produce minimal 
hepatic encephalopathy: evidence of this is the fact that microglial proliferation can 
also be found in cirrhosis without encephalopathy, suggesting that it plays a role much 
more associated with neuroprotection than production of tissue damage [11]. Current 
knowledge supports the theory that there is the necessity of the coexistence of hyper-
ammonemia and neuroinflammation, interacting synergistically, for the occurrence 
of neuropsychiatric disorders [10, 26]. In addition, at least one experimental study 
demonstrates that it is possible to produce cognitive deficits with the combination of 
these two factors, even in the absence of underlying liver disease [11].
6. The role of neurons
Hepatic encephalopathy has traditionally been assumed to be a metabolic 
disorder that affects glial cells but maintains the neuronal architecture preserved. 
However, this belief is easily contradicted by the presence of neuronal loss in its 
most extreme form: hepatocerebral degeneration. Such disorder is characterized by 
chronic manifestations (ataxia, dysarthria, apraxia, and parkinsonian symptoms), 
often associated with repeated and prolonged episodes of hepatic encephalopathy. 
Its anatomopathological study demonstrates not only astrocytic changes, but also 
neuronal loss in the basal ganglia, cerebral cortex, and cerebellum [15].
Most patients who develop episodes of hepatic encephalopathy demonstrate 
some degree of brain injury. Studies have shown that previous episodes of hepatic 
encephalopathy are risk factors for the development of cognitive impairment, 
which persists even after hepatic transplantation. In MRI, these findings are related 
to the fall of N-acetylaspartate in spectroscopy, a marker of neuronal density. This 
loss may be greater in some brain areas, such as the basal ganglia, which are particu-
larly sensitive to oxidative stress injury, which explains some of its more prominent 
clinical manifestations, such as movement disorders [15].
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It is known that in normal individuals, nitric oxide acts as a retrograde neu-
rotransmitter to the neurons, activating the guanylate cyclase, with consequent 
increase of the cyclic GMP (cGMP) and decrease of the intracellular influx of 
chlorine in the glycine receptors. The resulting electrochemical imbalance decreases 
the threshold of neuronal depolarization, facilitating the generation of action 
potentials, with subsequent intracellular influx of calcium through ionotropic 
channels, which amplifies the phosphorylating cascade of the calcium-calmodulin 
complex, in a process that culminates with learning [29].
Hyperammonemia induces an increased expression of nitric oxide synthase in 
astrocytes, promoting the formation of excessive amounts of nitric oxide, which 
diffuses into the extracellular environment. Prolonged hyperexposure of neurons 
adjacent to nitric oxide depletes the formation of cGMP, but the activity of nitric 
oxide synthase remains unchanged. The result is a high intraneuronal calcium 
influx and subsequent activation of NADPH oxidase, leading to the formation 
of superoxide. Superoxide and nitric oxide then combine to form the free radical 
peroxynitrite, in another vicious cycle that results in apoptosis [12]. In addition, 
neuronal ATP depletion is observed because of low nucleotide synthesis and high 
degradation rate, although its levels do not appear to correlate linearly with the 
concentration of glutamine and ammonia in the brain parenchyma [21].
Cyclic GMP also plays an important role in the reduction of neuroinflamma-
tion and microglial activation. It is known that this reduction is associated with 
an increase in the concentration of IL-1b and TNFα receptors [28]. The fact that 
chronic hyperammonemia promotes decreased cGMP production has been explored 
as a potential target for drug-based experimental treatments that increase the 
concentration of cGMP by inhibiting its degradation (e.g., sildenafil and zaprinast). 
One of the major obstacles to this strategy, however, is the fact that cGMP seems 
to act within narrow concentration limits, above which its accumulation becomes 
equally counterproductive to neuronal activity [29].
Under normal conditions, glutamine and glutamate synthesized by astrocytes 
are transferred to neurons, which internalize them via excitatory amino acid 
transporters 1 and 2 (EEAT1 and EEAT2). In neurons and astrocytes, the storage 
process of glutamate within presynaptic vesicles depends on the activity of vesicular 
glutamate transporters (VGLUT), which have three isoforms (VGLUT1–3). The 
VGLUT3 isoform, expressed mainly by astrocytes, is easier to release glutamate 
than the VGLUT1 and VGLUT2 isoforms found in neurons, which depend on 
intracellular calcium variations. That is the reason why astrocytes are more likely 
to release accumulated vesicular glutamate than neurons [4, 12]. Moreover, gluta-
mate is able to donate amines for the synthesis of serine, a precursor amino acid 
of glycine, increasing its synthesis and, consequently, of ammonia in the brain 
parenchyma [19]. Hyperammonemia, on the other hand, reduces the expression of 
EEAT1 and 2 on the neuronal surface, impairing its capacity of uptake. The result 
is the extracellular accumulation of glutamate, with consequent hyperactivation of 
adjacent receptors. This sequence of events seems to be the key in the pathophysiol-
ogy of hepatic encephalopathy [4, 12].
7. Effects on neural networks
Cognitive functions—attention, executive functions, memory, visuospatial 
skills, language, and social cognition—are the emerging results of neurotransmis-
sion [26]. They depend on the cooperation of multiple cortical areas, connected to 
each other through the white matter by bundles and fascicles of axonal fibers, in 
circuits known as neural networks. Changes in the synchronization of the activity 
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of these different regions contribute to the appearance of neurological deficits. This 
synchronization depends on the integrity of the white matter, which modulates the 
information processing speed [30].
During the progression of hepatic encephalopathy, the diffusion-weighted 
imaging on MRI demonstrates cumulative abnormalities in the white matter. In 
addition to interstitial edema, there may be macroscopic atrophy of the white mat-
ter and damage to the microstructural integrity of bundles and fascicles. Studies in 
patients with cirrhosis have shown that these changes correlate with the incidence 
of attention deficit, executive dysfunction, and increase in the number of falls [30]. 
The largest reductions appear to occur in the frontal white matter and in the globus 
pallidus [27]. In addition, cortical thickness decreases in several regions, such as the 
lateral superior temporal gyrus and the precuneus, which may also present correla-
tions, respectively, with attention and visuospatial deficits [30].
The final result of the accumulation of toxic, metabolic, cellular, and immuno-
logical alterations produced by liver failure and portosystemic shunt is the occur-
rence of dysfunction in the main axes of neurotransmission [31]. It is important 
to emphasize, however, that a same system may be involved with more than one 
cognitive function and that the mechanisms that lead to cognitive impairment are 
different from those involved in motor impairment [26]. Table 1 summarizes the 
main changes found in neurotransmission. The most known repercussions for each 
neural system will be discussed below.
Neurotransmission changes in hepatic encephalopathy





Increased release of neurotransmitters at 
presynaptic terminals
↑ Glutamate (VGLUT3) [4]
Decreased reuptake of neurotransmitters at 
presynaptic terminals
↑ Glutamate (↓ EEAT1 and 2) [4]
↑ GABA (reversal of GAT3) [32]
Increased degradation of neurotransmitters 
in the synaptic cleft
↑ GABAergic modulatory neurosteroids [33]
↓ Acetylcholine (↑ acetylcholinesterase and 
butyrylcholinesterase)
[34]
↓ Serotonin (↑ MAO-A) [35]
Modulation of receptor activity at 
postsynaptic terminals
↑ GABAergic modulatory neurosteroids [12, 26]
↑ Activity of metabotropic and ionotropic 
glutamatergic receptors (AMPA)
[26]
↓ Activity of adenosinergic receptors [36]
Changes in signal transduction cascade at 
postsynaptic terminals
↑ Intracellular calcium [12]
↑ cGMP [28]
Increased synthesis of retrograde 
neurotransmitters at postsynaptic terminals
↑ Nitric oxide [29]
Table 1. 
Main alterations found in neurotransmission in hepatic encephalopathy.
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8. Effects on the glutamatergic system
Glutamate is the main excitatory neurotransmitter of the central nervous system 
[31]. Two glutamatergic circuits are particularly important in the pathophysiology of 
hepatic encephalopathy: (1) an yet unproven hypothetic pathway that would descend 
from the frontal lobe and (2) the perforant pathway originated in the entorhinal cortex.
It is believed that the frontal descending pathway (Figure 1) originates in layer 
V pyramidal neurons and projects to the centers of other neurotransmitters in the 
brainstem. There, it performs synapses with dopaminergic neurons of the ventral 
tegmental area and the substantia nigra, the serotonergic neurons of raphe nuclei 
and noradrenergic neurons of the locus coeruleus, influencing their activity [37]. If 
this hypothesis is correct, glutamatergic hyperactivity would act as a final pathway 
common to the changes induced by hyperammonemia and neuroinflammation, dis-
turbing other neurotransmission systems, in steps that would invoke neuropsychi-
atric symptoms, and, in more severe cases, cause coma [4]. In addition, the frontal 
descending pathway would act as a “brake” for the dopaminergic pathway that leaves 
the ventral tegmental area toward the accumbens nucleus (located between the puta-
men and the caudate nucleus), influencing its activity through inhibitory GABAergic 
interneurons in the brainstem. This would result in tonic inhibition of dopamine 
release, with important consequences for executive and motor functions [37].
The perforant pathway (Figure 2) originates in the medial portion of the tem-
poral cortex, called the entorhinal cortex, and projects to the granular cells of the 
dentate gyrus. The axons of these cells form a pathway of mossy fibers, which goes 
to the Cornu Ammonis (CA) or Ammon’s horn, more precisely to the pyramidal cells 
of the CA3 region. Then, the pyramidal cells emit excitatory collaterals, the Schaffer 
collaterals, that go to the pyramidal cells of the CA1 region. A brief discharge of 
high-frequency stimuli in any of these three components of the perforant pathway 
increases the excitatory postsynaptic potentials in hippocampal neurons, which can 
last for hours, days, or even weeks. This facilitation is called long-term potentiation 
and, in addition to the hippocampus, also occurs in the amygdala, striatum (puta-
men and caudate nucleus), and cerebellar Purkinje cells, being essential for the 
formation of new traces of memory and learning [29, 32].
Figure 1. 
The frontal descending pathway would originate in the frontal cortex and influence directly or indirectly 
(through inhibitory interneurons) the activity of the neurotransmitter centers of the brainstem. AN: accumbens 
nucleus, GP: globus pallidus, RN: raphe nucleus, S: striatum, SN: substantia nigra, and T: thalamus.
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Glutamate receptors are classified as metabotropic (coupled to G protein) and 
ionotropic (bound to ion channels). There are at least eight subtypes of metabo-
tropic receptors and three classes of ionotropic receptors named according to 
agonists that selectively bind to them: NMDA (N-methyl-D-aspartate), AMPA 
(α-hydroxy-5-methyl-4-isoxazolepropionic acid), and kainate [37]. The first two 
have a particular relevance in hepatic encephalopathy, since the accumulation of 
glutamate in the synaptic clefts causes its hyperactivation, with excessive calcium 
influx [12]. This constant opening (tonic) of the ionotropic channels results in 
greater production of free radicals, with consequent neuronal apoptosis [26, 31]. 
The development of this process in the perforant pathway is a possible explanation 
for the episodic memory deficits presented by cirrhotics [12, 32]. Ammonia also 
induces apoptosis as a result of overproduction of nitric oxide [12], and this could 
explain why in some individuals such deficits become irreversible.
9. Effects on the GABAergic system
Cortical neurons are also modulated by GABA-secreting neighboring inter-
neurons, the main inhibitory neurotransmitter of the central nervous system [31]. 
Such cells organize themselves so that they can project their axons directly onto 
pyramidal cells, inhibiting glutamatergic neurotransmission, or extending their 
axons to other GABAergic interneurons that influence pyramidal cells, inhibiting 
the inhibition (and therefore, disinhibiting) of glutamatergic activity.
There are three main types (GABAA, GABAB, and GABAC) and numerous sub-
types of GABA receptors. GABAA and GABAC receptors are ionic channels sensitive to 
ligands and are part of a macromolecular complex that forms an inhibitory chlorine 
channel, whereas GABAB receptors are members of a different class, bound to protein 
G (metabotropic receptors). Depending on the composition of their subunits, GABAA 
receptors may be sensitive to benzodiazepines [37]. Nonbenzodiazepine-sensitive 
subtypes are located outside the synapses, capturing not only GABA that diffuses 
beyond it but also locally released neuroactive steroids as a consequence of microglial 
Figure 2. 
The perforant pathway originates in the entorhinal cortex (EC) and extends to the dentate gyrus (DG), from 
which neurons establish synapses with the CA3 and CA1 regions of the hippocampus, being involved with 
memory formation.
11
The Neurobiology of Hepatic Encephalopathy
DOI: http://dx.doi.org/10.5772/intechopen.86320
activation [31]. Nonbenzodiazepine-sensitive extrasynaptic GABAA receptors 
promote tonic inhibition of postsynaptic neurons, as opposed to phasic inhibition 
induced by benzodiazepine-sensitive GABAA receptors. In addition, GABAA receptors 
bind effectively to other modulators, such as alcohol and neurosteroids, in a different 
location than GABA agonists, the so-called allosteric sites [37].
Experimental studies have shown that, in chronic hepatic encephalopathy, 
increased GABAergic tone in the cerebellar cortex results in motor incoordination 
[28, 32]. Several theories have been proposed throughout the history to explain the 
elevation of the activity of this neurotransmission pathway: (1) increased GABA 
synthesis, (2) increased expression of GABAA receptors in postsynaptic terminals, 
(3) modulation of GABAA receptors by neuroactive steroids, and (4) reversion of 
the action of astrocytic GABA transporters [26, 28]. Most studies, however, show 
with confidence that: (1) although glutamine is a precursor for GABA, GABA 
synthesis is not increased in hepatic encephalopathy and (2) GABAA receptor 
expression does not change in chronic liver insufficiency [12, 21, 26]. Therefore, 
hypotheses (3) and (4) regarding the modulation of GABAA receptors by neuros-
teroids and reversion of the action of astrocytic transporters are those that require 
greater considerations.
Experimental studies with acute hepatic failure demonstrate that neurosteroids 
synthesized locally by microglial cells from cholesterol participate in the modula-
tion of GABAA receptor activity. Such neuroactive steroids may have an inhibitory 
effect (e.g., pregnenolone), functioning as positive allosteric modulators of GABAA, 
or excitatory receptors (e.g., allopregnanolone and tetrahydrodeoxycorticosterone), 
functioning as negative allosteric modulators of GABAA. It is believed that under 
the influence of hyperammonemia, both have their synthesis increased, but it is 
difficult to understand what emerges from the elevation of these two classes of hor-
mones, which have antagonic actions [26]. However, the current body of evidence 
supports the exploration of GABAA receptors as potential treatment targets (e.g., 
pregnenolone sulfate and bicuculline) in chronic hepatic encephalopathy [29].
On the other hand, some of the effects of GABA are terminated by the action of 
the GABA transporter (GAT), which acts reuptaking it at the presynaptic neuron 
terminal [37]. Although there is disagreement over the exact location of the four 
subtypes of GABA transporters (GAT1–4) in pre- and postsynaptic neurons and 
glial cells, it is clear that a key transporter in hepatic encephalopathy is GAT3 [38]. 
It is found on the surface of astrocytes and microglial cells, and its action can be 
reversed both in the presence of chronic hyperammonemia and/or glutamatergic 
hyperactivity, increasing the availability of GABA in the synaptic cleft and, conse-
quently, the GABAergic tone [28].
10. Effects on the dopaminergic system
The main dopaminergic projections originate predominantly in the neurotrans-
mission centers of the brainstem, especially the ventral tegmental area and substan-
tia nigra. They are modulated by glutamatergic and GABAergic neurons and, among 
other functions, regulate movements, reward, and cognition [37]. Three dopami-
nergic circuits are particularly important in the pathophysiology of chronic hepatic 
encephalopathy: (1) the mesocortical pathway, (2) the striatal-thalamic-cortical 
pathway, and (3) the nigrostriatal pathway.
The mesocortical pathway (Figure 3) originates in the cellular bodies of the ven-
tral tegmental area and extends to the prefrontal cortex, where it regulates execu-
tive functions [37]. The latter correspond to a set of abilities that, in an integrated 
way, allow the individual to direct behaviors to goals, to evaluate the efficiency and 
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Figure 4. 
The striatal-thalamic-cortical pathway originates in the dopaminergic neurons in the accumbens nucleus 
(AN) and extends to the globus pallidus (GP), where it regulates GABAergic interneurons that inhibit the 
activity of GABAergic interneurons in the thalamus (T), disinhibiting frontal glutamatergic activity. S: 
striatum.
adequacy of these behaviors; to abandon ineffective strategies in favor of others 
more efficient; and, thus, solve immediate, medium, and long-term problems [3]. 
It is hypothesized that the dopaminergic neurons of the ventral tegmental area are 
influenced by the glutamatergic neurons of the frontal descending pathway [37]. 
Moreover, in chronic hepatic encephalopathy, there is an increase in the activity of 
the enzyme monoamine oxidase B (MAO-B), with increased dopamine degrada-
tion, contributing to the development of a dysexecutive syndrome [33].
Experimental research demonstrates that the striatal-thalamic-cortical pathway 
(Figure 4) originates in the nucleus accumbens and projects to the internal globus 
pallidus, having an important role in the regulation of motor activity. It is believed 
that it is also influenced by the glutamatergic neurons from the frontal lobes, which 
Figure 3. 
The mesocortical pathway originates in the dopaminergic neurons in the ventral tegmental area and extends 
to the prefrontal cortex, where it regulates the executive functions. It is influenced by the activity of the frontal 
glutamatergic cells through GABAergic inhibitory interneurons. AN: accumbens nucleus, GP: globus pallidus, 
S: striatum, SN: substantia nigra, and T: thalamus.
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would excite inhibitory GABAergic interneurons. This would lead, in physiological 
circumstances, to a decrease in dopaminergic activity that extends from the accum-
bens nucleus to the internal globus pallidus, disinhibiting GABAergic interneurons 
that extend from the internal globus pallidus to the thalamus, where another group 
of GABAergic interneurons is located, with inhibitory projections to cortical gluta-
matergic cells. If the circuit is normofunctioning, very little dopamine is released 
from the accumbens nucleus, increasing the inhibitory activity that the internal 
globus pallidus exerts on the thalamus and preventing the latter from restricting 
the release of glutamate by the cortical neurons. The result is an increase in fron-
tal glutamatergic activity, responsible for motor function. In rats submitted to a 
portosystemic shunt, it is observed that hyperammonemia causes greater activation 
of glutamatergic metabotropic receptors in the accumbens nucleus, from which 
results a greater release of glutamate in the frontal region, a mechanism involved in 
the appearance of mini-asterixis [26]. It is also hypothesized that the portosystemic 
shunt can promote a cerebral deposition of manganese, which characteristically 
generates a hypersignal in the globus pallidus in T1-weighted sequence on MRI [9]. 
Moreover, manganese also has a predilection for deposition in substantia nigra, 
with a profound toxic action on the dopaminergic neurons, which could induce 
or aggravate the parkinsonian symptoms of hepatic encephalopathy [10]. Human 
studies, however, do not demonstrate a correlation between the hyperintensity of 
the globus pallidus and the severity of motor symptoms [27].
The nigrostriatal pathway (Figure 5) extends from the dopaminergic cell bodies 
of the substantia nigra to the striatum, forming part of the extrapyramidal system. It 
is modulated by the glutamatergic pathway and the accumbens nucleus, both being 
connected to it through inhibitory GABAergic interneurons. In rats submitted to a 
portosystemic shunt, hyperammonemia causes activation of glutamatergic ionotropic 
AMPA receptors in the accumbens nucleus [26], and neuroinflammation decreases 
the expression of glutamatergic transporters EEAT1 and VGLUT1, increasing the 
availability of glutamate in substantia nigra [11]. The result of this glutamatergic 
hyperactivity is an increase in inhibition of the nigrostriatal pathway [26], whose 
deficiency in dopaminergic release leads to the onset of parkinsonian symptoms such 
as stiffness, bradykinesia, and tremor [37]. Interestingly, experimental studies show 
Figure 5. 
The nigrostriatal dopaminergic pathway originates from the substantia nigra (SN) and extends to the striatum 
(S), where it regulates the extrapyramidal system. It is inhibited by GABAergic interneurons in the accumbens 
nucleus (AN) or brainstem, the latter being modulated by frontal glutamatergic cells. GP: globus pallidus and 
T: thalamus.
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Figure 6. 
The cholinergic pathways originate in the basal forebrain (BF) and reticular formation (RF). They extend to 
the prefrontal cortex and medial portion of the temporal cortex. AN: accumbens nucleus, GP: globus pallidus, 
S: striatum, and T: thalamus.
that the activation of glutamatergic metabotropic receptors in the substantia nigra 
can also cause a decrease in the locomotion of rodents, since the substantia nigra has a 
second pathway of GABAergic neurons that extends into the thalamus, where a group 
of GABAergic interneurons inhibit motor cells, resulting in hypokinesia [26].
11. Effects on the cholinergic system
Acetylcholine is a neurotransmitter and modulator that, when bound to nicotinic 
receptors, favors neuronal excitability, and when bound to muscarinic receptors 
(mainly of the M2 subtype), inhibits the inhibitory activity triggered by the activation 
of GABAA receptors, i.e., disinhibits the postsynaptic terminal [31]. Two cholinergic 
pathways are particularly important in the pathophysiology of hepatic encephalopathy 
(Figure 6): (1) those originating from the ascending activating reticular system in the 
brainstem (particularly the laterodorsal tegmental nuclei and pedunculopontine nuclei) 
and (2) those originating from the basal forebrain, an area that includes the nucleus 
basalis of Meynert, the medial septal nucleus, and the diagonal band of Broca [37].
The projections of acetylcholine that originate in the ascending reticular activat-
ing system extend to the prefrontal cortex, basal forebrain, thalamus, hypothala-
mus, amygdala, and hippocampus; they are considered to be involved in vigilance 
(sustained attention) [39]. Cholinergic neurons that originate in the basal forebrain 
extend to the prefrontal cortex, hippocampus, and amygdala; they are involved 
with the formation of episodic memory [37].
The effects of acetylcholine are terminated by two enzymes, acetylcholinesterase 
and butyrylcholinesterase. Both convert acetylcholine to choline, which is then 
transported back to the presynaptic terminal for further synthesis of this neu-
rotransmitter [37]. Cirrhosis is associated with an increase of approximately 30% in 
acetylcholinesterase activity in humans, which contributes to a decrease in ace-
tylcholine levels and a consequent potentiation of the effects of GABAergic tonus 
[34]. Little is known about how chronic hyperammonemia and neuroinflammation 
induce changes in the cholinergic system [31]. There is no correlation, for example, 
between serum ammonia levels and acetylcholinesterase activity [34]. However, 
experimental studies have shown that the increased availability of acetylcholine in 
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the synaptic cleft, either by direct administration or by inhibition of its degrada-
tion, is related to the reduction in glutamate neurotoxicity and improvement in the 
severity of hepatic encephalopathy [31].
12. Effects on the serotonergic system
Serotonin is a neurotransmitter and modulator that favors the excitability of cor-
tical neurons; a decrease in serotonergic tonus potentiates the effects of increased 
GABAergic tone [31]. Serotonergic neurons have both ascending and descending 
projections (Figure 7). The ascending projections originate in the raphe nuclei in 
the brainstem and extend to the cerebellum, hypothalamus, thalamus, amygdala, 
hippocampus, striatum, accumbens nucleus, basal forebrain, and prefrontal cortex 
[37]. They are related to the regulation of mood, hunger, impulsivity, and circa-
dian rhythm [35]. The descending projections extend to the lower portions of the 
brainstem and spinal cord, being important for pain regulation [37].
The dysfunction of the serotonergic system has been widely documented in both 
minimal hepatic encephalopathy and overt hepatic encephalopathy: it underlies several 
early neuropsychiatric disorders in the disease, such as mood and sleep disorders. 
Serotonin levels correlate with the severity of cirrhosis and the degree of portosystemic 
shunt [35]. There is an increase in the circulation of l-tryptophan, the precursor amino 
acid of this neurotransmitter, in blood and cerebrospinal fluid. It is hypothesized that 
hyperammonemia not only stimulates serotonin synthesis, but also its degradation 
by the enzyme monoamine oxidase A (MAO-A), which is shown by the concomitant 
increase of the main product of its metabolism, 5-hydroxyindoleacetic acid [31, 33, 35].
13. Effects on the histaminergic system
Histamine acts in conjunction with serotonin to regulate the circadian rhythm 
[31]. Histaminergic neurons originate in the tuberomammillary nucleus of the 
hypothalamus and make extensive projection throughout the central nervous 
system, including the spinal cord (Figure 8) [37]. Significant increase in histamine 
Figure 7. 
The ascending serotonergic pathway originates in the raphe nucleus (RN) and extends to the medial portion of 
the temporal cortex and prefrontal cortex, while the descending pathway modulates the activity of the spinal 
cord. AN: accumbens nucleus, GP: globus pallidus, S: striatum, and T: thalamus.
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Figure 9. 
The ascending noradrenergic pathway originates in the locus coeruleus (LC) and extends to the thalamus (T), 
medial portion of the temporal cortex, and prefrontal cortex, while the descending pathway modulates the 
activity of the spinal cord. AN: accumbens nucleus, GP: globus pallidus, and S: striatum.
levels have been documented in patients with hepatic encephalopathy [31]. 
Histamine is produced from the amino acid histidine [37]; hyperammonemia 
increases both the concentration of histidine and the activity of its membrane trans-
porter into the histaminergic neurons, stimulating the synthesis of histamine [31].
14. Effects on the noradrenergic system
In the 1970s, it was believed that hepatic encephalopathy might reflect a distur-
bance in catecholaminergic metabolism [31]. The main projections of noradrenaline 
originate in the locus coeruleus, although there are also some in the laterodorsal 
tegmental nuclei of the brainstem (Figure 9). They can be ascending or descending. 
Figure 8. 
The ascending histaminergic pathway originates in the hypothalamus and extends to the medial portion of the 
temporal cortex and prefrontal cortex, while the descending pathway modulates the activity of the spinal cord. 
AN: accumbens nucleus, GP: globus pallidus, S: striatum, and T: thalamus.
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Ascending projections regulate vigilance and mood: they end diffusely throughout 
the brain, including many of the same sites for which serotoninergic pathways extend, 
although there are few noradrenergic extensions to the striatum and accumbens 
nucleus. The descending projections extend to the spinal cord and regulate pain [37].
Currently, it is widely accepted that changes in catecholaminergic metabolism do 
not precipitate hepatic coma [31]. Studies have shown that, in patients with cirrho-
sis, there is no decrease in norepinephrine concentration in most brain regions, with 
the maintenance of α1 and α2 receptor density. However, it is assumed that more 
subtle chronic changes may coexist with some neuropsychiatric symptoms, such as 
depression and anxiety [31, 33].
15. Effects on the adenosinergic system
Adenosine is a modulator of neuronal excitability, which inhibits postsynaptic 
potentials generated by classical neurotransmitters, such as glutamate, GABA, 
dopamine, and serotonin. Since 1960s, studies have shown reduced expression of 
adenosinergic receptors in the striatum and cortex of patients with mild hepatic 
encephalopathy [31].
Although the mechanisms through which adenosine exerts its function are still 
not fully understood [36], it is known that the decrease in the expression of its 
receptors occurs in the early stages of the disease and contributes to an increase 
in glutamatergic activity, potentializing its excitotoxic effects, while increasing 
GABAergic tone, also potentializing its inhibitory effects [31].
16. Final Considerations
The twentieth century provided the greatest scope of information on the 
neurobiology of hepatic encephalopathy throughout history, but failed to create 
an integrated theory that would allow the adoption of more effective intervention 
strategies. This was due to the reductionist view that a single process would have 
primacy over the others, with the emphasis on hyperammonemic theory being 
its greatest example. As other factors such as the composition of the intestinal 
microbiota, synergism with neuroinflammation, and the role of glutamatergic and 
GABAergic tonus balance were discovered, it became clear that this traditional and 
linear view of scientific research allows the understanding of the initial state of 
multiple dysfunctional systems, but is not able to predict the overall behavior of the 
disease. As twenty-first century progresses, it is imperative to incorporate concepts 
such as convergence, emergency, and complexity into research related to the theme, 
both in diachronic and synchronic processes, for the construction of a true dynamic 
and integrated vision that allows more effective therapeutic interventions, in a total 
hermeneutical cycle.
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